Article Summary
March 2, 2021
Risk Factors for Illness Severity among Pregnant Women with Confirmed SARS-CoV-2 Infection – Surveillance for Emerging Threats to Mothers and Babies Network 20 State Local and Territorial Health Departments March 29 2020 -January 8 2021
[Pre-print, not peer-reviewed] Risk factors for developing moderate-to-severe COVID during pregnancy included age 30-39 years, Black/Non-Hispanic race/ethnicity, healthcare occupation, pre-pregnancy obesity, chronic lung disease, chronic hypertension, cardiovascular disease, pre-gestational diabetes or gestational diabetes. The study was conducted by the CDC from March 2020 to January 2021 and included 5,963 pregnant women with laboratory confirmed SARS-CoV-2…
REACT-2 Round 5 Increasing Prevalence of SARS-CoV-2 Antibodies Demonstrate Impact of the Second Wave and of Vaccine Roll-out in England
[Pre-print, not peer-reviewed] A nationwide cross-sectional study in the England (n=172,000) conducted between January 26 to February 8, 2021 found that the SARS-CoV-2-specific antibody seroprevalence representative of the national population was 14% overall. This figure included seroprevalence due to both immunization and infection. Seroprevalence in unvaccinated people was highest in London and among members of…
Negligible Impact of SARS-CoV-2 Variants on CD4+ and CD8+ T Cell Reactivity in COVID-19 Exposed Donors and Vaccinees
[Pre-print, not peer-reviewed] Bioinformatic analysis suggests that memory T cells generated either by mild SARS-CoV-2 infection (n=11) or mRNA vaccines will not be affected by currently circulating variants. No significant differences were found in the capacity of CD4+ or CD8+ T cells isolated either from convalescent patients following mild disease or vaccinated individuals to recognize…
Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
A single dose of mRNA vaccine (Pfizer or Moderna vaccine) elicited higher antibody and neutralization titers in health care workers (n=59) with previous serology-confirmed SARS-CoV-2 infection compared to healthcare workers who were seronegative at baseline. At 14 days post-vaccination, antibody binding strength to SARS-CoV-2 antigens from participants with both asymptomatic and symptomatic prior infection were…
Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19
[Pre-print, not peer-reviewed] A longitudinal study in California found that SARS-CoV-2-specific T cell responses remained largely stable up to 9 months following SARS-CoV-2 infection (n=70). Stronger CD4+ T cell responses were associated with initial disease severity as well as neutralizing antibody levels, whereas pre-existing lung disease predicted long-term CD8+ T cell responses. While 36% of…
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
The Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the single-dose Johnson & Johnson COVID-19 vaccine in persons at least 18 years. The February 28, 2021 recommendation was based on a transparent evidence-based review of all available data, primarily informed by the interim analysis of the Phase 3 clinical trials…
Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults
[Pre-print, not peer-reviewed] The two-dose Novavax recombinant nanoparticle vaccine candidate “NVX-CoV2373” induced robust IgG-anti-spike protein and neutralizing antibody titers against SARS-CoV-2 in both young and older participants, according to results from a Phase I/II trial (n=1,283). >98% of participants had seroconversion in both age groups fourteen days after the second dose. Reactogenicity was predominantly mild…
Reduced Antibody Cross-Reactivity Following Infection with B.1.1.7 than with Parental SARS-CoV-2 Strains
[Pre-print, not peer-reviewed] Convalescent sera from patients infected with the SARS-CoV-2 B.1.1.7 variant demonstrated reduced activity against reference strains from earlier in the pandemic. Neutralizing activity of sera isolated from patients that had confirmed infection by the SARS-CoV-2 B.1.1.7 variant (n=29) was reduced against a parental reference strain isolated from Wuhan by 3.4-fold. In contrast,…
A Shorter Symptom-Onset to Remdesivir Treatment (SORT) Interval Is Associated with a Lower Mortality in Moderate-to-Severe COVID-19: A Real-World Analysis
In a retrospective analysis of patients with moderate-to-severe COVID-19 in India (n=346), patients receiving remdesivir 9 days or less after symptom onset had significantly lower all-cause mortality compared to those who received it after 9 days (18% vs 34%). Odds of death were reduced by 37% among patients receiving remdesivir <=9 days post-symptom onset compared…
Household COVID-19 Risk and in-Person Schooling
[Pre-print, not peer-reviewed] School-based mitigation measures reduced the odds of reporting COVID-19 like illness (CLI) and/or a positive SARS-CoV-2 PCR test result among household members living with a child attending in-person learning, according to an online survey of over 2 million US respondents conducted between November 2020 to January 2021. While the risk of reporting…
Previous page Next page